文献速递胸部肿瘤

Hsp90抑制剂luminespib在EGFR外显子20插入突变NSCLC中的活性

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
PubMed 文献 · Ann Oncol · 2018-01-01

这项II期试验评估了Hsp90抑制剂luminespib在29例EGFR外显子20插入突变的IV期NSCLC患者中的活性。主要终点客观缓解率为17%,中位无进展生存期2.9个月,中位总生存期13个月,达到预设有效性目标。常见毒性包括腹泻、视觉改变和乏力。

要点

  • luminespib在EGFR ins20的NSCLC中客观缓解率达17%。
  • 中位无进展生存期2.9个月,中位总生存期13个月。
  • 常见毒性为腹泻、视觉改变和乏力,多为低级别可逆。

核心结论

  • 研究达到主要终点,提示luminespib可能对EGFR ins20晚期NSCLC有活性。
  • luminespib总体耐受性良好,但可逆性低级别眼毒性常见。
  • 值得进一步研究luminespib及其他Hsp90抑制剂在该人群中的应用。

研究设计与样本

  • II期临床试验,纳入29例经当地检测确认EGFR ins20且至少接受过一线治疗的IV期NSCLC患者。
  • 主要终点为客观缓解率,预设有效性目标率为20%。
  • 次要终点包括无进展生存期、总生存期、安全性和按EGFR ins20亚型的缓解。

主要发现

  • 29例患者中客观缓解率为17%,中位无进展生存期为2.9个月(95%CI 1.4-5.6)。
  • 中位总生存期为13个月(95%CI 4.9-19.5)。
  • 11/29(38%)患者达到部分缓解或疾病稳定≥3个月,超过预设有效性目标率。
  • 最常见的luminespib相关毒性为腹泻(83%)、视觉改变(76%)和乏力(45%)。

关键数值与推荐

  • 预设有效性目标率为20%,定义为部分缓解加疾病稳定≥3个月的比例。
  • 实际达到部分缓解或疾病稳定≥3个月的比例为11/29(38%)。

临床怎么用

  • 对于EGFR ins20的晚期NSCLC患者,luminespib可能作为一种治疗选择。
  • 治疗期间需监测腹泻、视觉改变和乏力等毒性。

局限性

  • 研究因药物供应终止于2017年2月28日而提前停止,终止时3例患者仍在治疗。
  • 样本量较小,共29例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR mutations that are generally refractory to first/second generation EGFR inhibitors. We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20. PATIENTS AND METHODS: Twenty-nine patients with stage IV NSCLC with EGFR ins20 identified on local testing and at least one prior therapy were enrolled on the trial between August 2013 and October 2016. The primary end point was objective response rate (ORR), with a pre-determined target rate of effectiveness [defined as the rate of partial response (PR) plus stable disease (SD) lasting ≥3 months] of 20%. Secondary end points were PFS, overall survival (OS), safety and response by EGFR ins20 subtype. RESULTS: Among the 29 patients (18 females, median age 60 years) the ORR was 17%, median progression-free survival was 2.9 months (95% CI 1.4-5.6) and median OS (mOS) was 13 months (95% CI 4.9-19.5). The results exceeded the pre-determined target rate of effectiveness with 11/29 (38%) patients having a PR or an SD ≥3 months. The most common luminespib-related toxicities were diarrhea (83%), visual changes (76%) and fatigue (45%). All study treatment was stopped on 28 February 2017 due to dissolution of study drug availability; 3 patients were on treatment at study termination. CONCLUSION: The study met its primary end point, suggesting that luminespib may be an active therapy for advanced NSCLC patients with EGFR ins20. Luminespib is generally well-tolerated, though reversible low-grade ocular toxicity is common. Further study of luminespib and other hsp90 inhibitors in this population is warranted. STUDY REGISTRATION (CLINICALTRIALS.GOV): NCT01854034.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Piotrowska Z, Costa DB, Oxnard GR, et al. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018. PMID: 30351341. doi:10.1093/annonc/mdy336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。